KAT3A / CBP Polyclonal Antibody, AbBy Fluor-350 Conjugated, BF350, Rabbit

Artikelnummer: BSS-BS-12395R-BF350
Artikelname: KAT3A / CBP Polyclonal Antibody, AbBy Fluor-350 Conjugated, BF350, Rabbit
Artikelnummer: BSS-BS-12395R-BF350
Hersteller Artikelnummer: bs-12395R-BF350
Alternativnummer: BSS-BS-12395R-BF350-100
Hersteller: Bioss
Wirt: Rabbit
Kategorie: Antikörper
Applikation: FC, IF
Spezies Reaktivität: Human, Mouse, Rat
Konjugation: BF350
Alternative Synonym: CBP, CBP/p300, CBP_HUMAN, CREB binding protein, CREB-binding protein, CREBBP, Cyclic AMP responsive enhancer binding protein, Cyclic AMP-responsive enhancer binding protein, KAT3A, RSTS, RTS, Rubinstein Taybi syndrome, Rubinstein-Taybi syndrome.
Cyclic AMP-regulated gene expression frequently involves a DNA element designated the cAMP-regulated enhancer (CRE). Many transcription factors bind to this element, including the protein CREB, which is activated as a result of phosphorylation by protein kinase A. It has been shown that protein kinase A-mediated CREB phosphorylation results in its binding to a nuclear protein designated CBP (for CREB-binding protein). These findings suggest that CBP has many of the properties expected of a CREB co-activator. Another high molecular weight transcriptional adapter protein, designated p300, is characterized by three cysteine- and histidine-rich regions, of which the most carboxy terminal region specifically binds the adenovirus E1A protein. p300 molecules lacking an intact E1A binding site bypass E1A repression, even in the presence of high concentrations of E1A. Sequence analysis of CBP and p300 has revealed substantial homology, arguing that these proteins are members of a conserved family of co-activators.
Klonalität: Polyclonal
Konzentration: 1ug/ul
NCBI: 1387
Puffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Quelle: KLH conjugated synthetic peptide derived from human KAT3A/CBP
Target-Kategorie: KAT3A / CBP
Application Verdünnung: IF(), FCM(1ug/Test)